OctoPlus signed agreement with leading pharmaceutical company

Published : Wednesday, January 11, 2012
OctoPlus signed agreement with leading pharmaceutical company

OctoPlus N.V. announced that it has signed a feasibility agreement with a leading US-based pharmaceutical company, aimed at developing a controlled release formulation of the client’s therapeutic compound for local delivery into joints. 


This contract covers initial activities in developing a controlled release formulation of an undisclosed compound using our proprietary drug delivery technology PolyActive®. If the evaluation is successful, the project may progress into a full development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.